相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
David M. O'Malley et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
V Makker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations
Barbara Willvonseder et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors
Toshio Shimizu et al.
CLINICAL CANCER RESEARCH (2021)
POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy
Dandan Dong et al.
FRONTIERS IN ONCOLOGY (2021)
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency
K. Ludford et al.
ANNALS OF ONCOLOGY (2021)
A phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001
L. Farinas-Madrid et al.
ANNALS OF ONCOLOGY (2021)
Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
Wei Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PMC: A more precise classifier of POLE mutations to identify candidates for immune therapy.
Fadl Zeineddine et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer
Marisa R. Moroney et al.
MOLECULAR CARCINOGENESIS (2021)
Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities
Yifan Xu et al.
FRONTIERS IN IMMUNOLOGY (2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin et al.
RADIOTHERAPY AND ONCOLOGY (2021)
PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells Differences Across Histologic and TCGA-based Molecular Subgroups
Annukka Pasanen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Proteogenomic Characterization of Endometrial Carcinoma
Yongchao Dou et al.
CELL (2020)
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma
Chanhee Han et al.
GYNECOLOGIC ONCOLOGY (2020)
Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer
Nathaniel L. Jones et al.
GYNECOLOGIC ONCOLOGY (2020)
Interpretation of somatic POLE mutations in endometrial carcinoma
Alicia Leon-Castillo et al.
JOURNAL OF PATHOLOGY (2020)
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
Emanuele Perrone et al.
MOLECULAR ONCOLOGY (2020)
CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies
Alba Rodriguez-Garcia et al.
MOLECULAR THERAPY (2020)
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
Ryosuke Okamura et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer
Neal C. Fiamchander et al.
FRONTIERS IN IMMUNOLOGY (2020)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.
Stephanie Lheureux et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Exploiting the folate receptor α in oncology
Mariana Scaranti et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
B. J-C. Rousseau et al.
ANNALS OF ONCOLOGY (2020)
Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer
P. A. Konstantinopoulos et al.
ANNALS OF ONCOLOGY (2020)
Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells
Lea Lazzerini et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution
Alexej Ballhausen et al.
NATURE COMMUNICATIONS (2020)
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
Yuxiao Song et al.
FRONTIERS IN IMMUNOLOGY (2020)
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer A Nonrandomized Phase 1 Clinical Trial
Ana Oaknin et al.
JAMA ONCOLOGY (2020)
Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors
Vladimir Roudko et al.
CELL (2020)
Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes
Tao Jiang et al.
JOURNAL OF CANCER (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
Tanios Bekaii-Saab et al.
CLINICAL CANCER RESEARCH (2019)
Antibody-drug conjugates in gynecologic malignancies
Elizabeth K. Lee et al.
GYNECOLOGIC ONCOLOGY (2019)
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S. de Bono et al.
LANCET ONCOLOGY (2019)
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato et al.
PLOS ONE (2019)
Phenotype of POLE-mutated endometrial cancer
Sara Imboden et al.
PLOS ONE (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.
Maria M. Rubinstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial
Kenji Tamura et al.
CANCER SCIENCE (2019)
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer
Jennifer Taylor Veneris et al.
GYNECOLOGIC ONCOLOGY (2019)
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients
Tommy A. Brown et al.
CANCER MEDICINE (2019)
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
Joyce F. Liu et al.
GYNECOLOGIC ONCOLOGY (2019)
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Aaron M. Goodman et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors
Guoliang Qiao et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2019)
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Jason J. Luke et al.
CLINICAL CANCER RESEARCH (2019)
Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Marthe M. de Jonge et al.
CLINICAL CANCER RESEARCH (2019)
Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression
Charles W. Ashley et al.
GYNECOLOGIC ONCOLOGY (2019)
Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+lymphocytes
Suzanne Crumley et al.
MODERN PATHOLOGY (2019)
Clinical actionability of molecular targets in endometrial cancer
Mary Ellen Urick et al.
NATURE REVIEWS CANCER (2019)
Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series
S. Kommoss et al.
ANNALS OF ONCOLOGY (2018)
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N. Fader et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas
Anne Mills et al.
MODERN PATHOLOGY (2018)
In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
Gary Altwerger et al.
MOLECULAR CANCER THERAPEUTICS (2018)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen et al.
NATURE MEDICINE (2018)
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Jake S. O'Donnell et al.
SEMINARS IN CANCER BIOLOGY (2018)
Targeting Wnt/β-Catenin Signaling for Cancer Immunotheraoy
Bojun Wang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
1181PMutations in interferon gamma and antigen presentation pathways are frequent in hiper/ultra-mutated (HiMut) tumors and could be result of immune-editing processes in HiMut tumors
J M Piulats Rodriguez et al.
ANNALS OF ONCOLOGY (2018)
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
Takayuki Kimura et al.
CANCER SCIENCE (2018)
Impact of oncogenic pathways on evasion of antitumour immune responses
Stefani Spranger et al.
NATURE REVIEWS CANCER (2018)
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Tara E. Soumerai et al.
CLINICAL CANCER RESEARCH (2018)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
New insights into the role of EMT in tumor immune escape
Stephane Terry et al.
MOLECULAR ONCOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters
Janelle B. Pakish et al.
CLINICAL CANCER RESEARCH (2017)
Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
Kathleen N. Moore et al.
CANCER (2017)
Targeting angiogenesis in endometrial cancer - new agents for tailored treatments
Anselmo Papa et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro
Stefania Bellone et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2016)
Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab
Alessandro D. Santin et al.
CLINICAL CANCER RESEARCH (2016)
CD103 defines intraepithelial CD8+PD1+tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma
Hagma H. Workel et al.
EUROPEAN JOURNAL OF CANCER (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Janice M. Mehnert et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer
Ellen Stelloo et al.
ONCOTARGET (2016)
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Inge C. van Gool et al.
CLINICAL CANCER RESEARCH (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E. Howitt et al.
JAMA ONCOLOGY (2015)
DNA polymerase ? and exonuclease domain mutations in endometrial cancer
David N. Church et al.
HUMAN MOLECULAR GENETICS (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
Martin D. Forster et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Mullerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers
Jamie N. Bakkum-Gamez et al.
GYNECOLOGIC ONCOLOGY (2008)
Recombinant vaccinia/fowipox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
Elke Jaeger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer
AD Santin et al.
GYNECOLOGIC AND OBSTETRIC INVESTIGATION (2000)
分享论文
